SCHEMBL4045865

SCHEMBL4045865

CC(C)(C)c1ccc(C(=O)NC(CC2CC2)C(=O)N2CCC3C2C(=O)CN3S(=O)(=O)C(=O)c2cccnc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSK P43235 4/20 0.54
CTSS P25774 3/20 0.42
CTSV O60911 2/20 0.42
CTSL P07711 2/20 0.42
PREP P48147 2/20 0.38
FAP Q12884 1/20 0.38
RAB9A P51151 2/20 0.38
MAPT P10636 2/20 0.37
THRB P10828 1/20 0.37
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
NAMPT P43490 2/20 0.34
SLC2A1 P11166 1/20 0.34
ACE P12821 1/20 0.34
HTRA1 Q92743 1/20 0.34
NPC1 O15118 1/20 0.34
USP30 Q70CQ3 1/20 0.34
GPR132 Q9UNW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4040987 0.92 CTSK (0.65) CTSKCTSSCTSVCTSLPREP
SCHEMBL4040234 0.91 CTSK (0.54) CTSKCTSSCTSVCTSLPREP
SCHEMBL4040008 0.90 CTSK (0.53) CTSKCTSSCTSVCTSLPREP
SCHEMBL4044111 0.89 CTSK (0.52) CTSKCTSSPREPFAPRAB9A
SCHEMBL4042328 0.89 CTSK (0.51) CTSKCTSSPREPFAPRAB9A
SCHEMBL4043868 0.89 CTSS (0.45) CTSKCTSSCTSVCTSLPREP
SCHEMBL4043933 0.88 CTSK (0.51) CTSKCTSSCTSVCTSLPREP
SCHEMBL4040540 0.88 CTSK (0.51) CTSKCTSSCTSVCTSLPREP
SCHEMBL4041797 0.88 CTSK (0.50) CTSKCTSSRAB9AACEUSP30
SCHEMBL4044651 0.88 CTSK (0.50) CTSKCTSSCTSVCTSLPREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US claimed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP disclosed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US disclosed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 EP disclosed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS CTSK 2/4885CTSS 3/4885CTSV 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.